Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

RBC Says Verastem Interim Analysis In Ovarian Cancer Reinforces Enthusiasm

  • With the anticipation of a 2Q program update, Verastem Oncology (NASDAQ:VSTM) announced that its interim analysis findings for the RAMP 201 program for recurrent low-grade serous ovarian cancer (LGSOC) continue evaluation in both monotherapy and combination regimens. 
  • With incremental updates from ASCO, reiterated KOL enthusiasm, and more updates are upcoming in 2022 on a longer runway, RBC Capital continues to like the VSTM setup.
  • The company plans to complete enrollment of all four trial cohorts in the second half of this year.
  • Related: Truist Sees 350% Upside On This Cancer-Focused Biopharma Stock - Read Why.
  • It has reiterated the Outperform, Speculative Risk rating, and a price target of $5.
  • RBC Capitals believes VSTM has exhibited differentiating safety profile exhibited thus far, all of which it finds reassuring.
  • The analysts noted that around 6% had discontinued the trial based on treatment-related adverse events compared to ~30% for tyrosine kinase inhibitors' current standard of care.
  • However, the update has generated interest in the clarity around the planned regulatory interactions, which are still pending and will guide go-forward dosing and trial design. 
  • Price Action: VSTM shares are up 6.15% at $1.30 during the market session on the last check Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.